Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics and keeping the price target at $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis’s rating is based on several key factors that highlight Astria Therapeutics’ strong financial position and strategic developments. The company reported a better-than-expected EPS for 2Q25 and ended the quarter with a robust cash balance of $259.2 million. This financial strength is further bolstered by a recent licensing agreement with Kaken Pharmaceutical, which includes upfront and milestone payments that extend Astria’s cash runway into 2028.
Additionally, the partnership with Kaken Pharmaceutical is seen as a strategic move to enhance the commercial prospects of navenibart, Astria’s lead asset. The agreement not only provides financial support but also facilitates the Phase 3 ALPHA-ORBIT study in Japan, potentially expanding navenibart’s market reach. Furthermore, ongoing clinical trials, such as the Phase 1a trial of STAR-0310, are expected to yield promising results, potentially differentiating Astria’s offerings in the market. These factors collectively contribute to Pantginis’s Buy rating for Astria Therapeutics.
In another report released on August 6, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.